MA39211B1 - Composés tricycliques comme agents anti-cancers - Google Patents
Composés tricycliques comme agents anti-cancersInfo
- Publication number
- MA39211B1 MA39211B1 MA39211A MA39211A MA39211B1 MA 39211 B1 MA39211 B1 MA 39211B1 MA 39211 A MA39211 A MA 39211A MA 39211 A MA39211 A MA 39211A MA 39211 B1 MA39211 B1 MA 39211B1
- Authority
- MA
- Morocco
- Prior art keywords
- tricyclic compounds
- cancer agents
- compounds
- tricyclic
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La présente invention concerne des composés tricycliques (i), des compositions pharmaceutiquement acceptables contenant des composés de l'invention et des procédés d'utilisation desdites compositions dans le traitement de divers troubles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920500P | 2013-12-24 | 2013-12-24 | |
PCT/US2014/072031 WO2015100282A1 (fr) | 2013-12-24 | 2014-12-23 | Composés tricycliques comme agents anti-cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39211A1 MA39211A1 (fr) | 2018-08-31 |
MA39211B1 true MA39211B1 (fr) | 2019-01-31 |
Family
ID=52293305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39211A MA39211B1 (fr) | 2013-12-24 | 2014-12-23 | Composés tricycliques comme agents anti-cancers |
Country Status (33)
Country | Link |
---|---|
US (1) | US20160318928A1 (fr) |
EP (2) | EP3087071B1 (fr) |
JP (2) | JP6466456B2 (fr) |
KR (1) | KR102457145B1 (fr) |
CN (2) | CN108558871B (fr) |
AR (2) | AR099379A1 (fr) |
AU (1) | AU2014369982B2 (fr) |
BR (1) | BR112016013744B1 (fr) |
CA (1) | CA2934953C (fr) |
CL (1) | CL2016001629A1 (fr) |
CY (2) | CY1121076T1 (fr) |
DK (2) | DK3087071T3 (fr) |
EA (2) | EA201990240A1 (fr) |
ES (2) | ES2857848T3 (fr) |
HR (2) | HRP20181849T1 (fr) |
HU (2) | HUE054183T2 (fr) |
IL (1) | IL246359B (fr) |
LT (2) | LT3087071T (fr) |
MA (1) | MA39211B1 (fr) |
MX (1) | MX369491B (fr) |
MY (1) | MY176489A (fr) |
NZ (1) | NZ722326A (fr) |
PE (1) | PE20160844A1 (fr) |
PH (1) | PH12016500953A1 (fr) |
PL (2) | PL3466949T3 (fr) |
PT (2) | PT3087071T (fr) |
RS (2) | RS58014B1 (fr) |
SG (1) | SG11201605097SA (fr) |
SI (2) | SI3466949T1 (fr) |
TN (1) | TN2016000238A1 (fr) |
TW (2) | TWI726544B (fr) |
UY (1) | UY35916A (fr) |
WO (1) | WO2015100282A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10053454B2 (en) | 2013-02-27 | 2018-08-21 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
LT3087071T (lt) * | 2013-12-24 | 2018-11-12 | Bristol-Myers Squibb Company | Tricikliniai junginiai kaip priešvėžiniai agentai |
CN107074861A (zh) * | 2014-02-28 | 2017-08-18 | 密执安大学评议会 | 作为bet溴结构域抑制剂的9h嘧啶并[4,5‑b]吲哚和相关类似物 |
EP3307740B1 (fr) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | Composés 5h-pyrido[3,2-b]indole en tant qu'agents anticancéreux |
US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
EP3322448A4 (fr) * | 2015-07-16 | 2019-03-06 | Bioxcel Therapeutics, Inc. | Nouvelle approche pour le traitement du cancer par immunomodulation |
WO2017059319A2 (fr) * | 2015-10-02 | 2017-04-06 | Dana-Farber Cancer Institute, Inc. | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
WO2017124934A1 (fr) * | 2016-01-20 | 2017-07-27 | 宁波文达医药科技有限公司 | Dérivé de carboline contenant de la phosphine servant d'inhibiteur de bromodomaine |
JP6855505B2 (ja) * | 2016-01-20 | 2021-04-07 | ニンボー ウェンダ ファーマー テクノロジー エルティーディー. | ブロモドメイン阻害剤としてのカルボリン誘導体 |
EP3412669A4 (fr) * | 2016-02-05 | 2019-09-04 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | Composé tricyclique pour inhibiteur de protéine contenant un bromodomaine et préparation, composition pharmaceutique et son utilisation |
BR112018067330A2 (pt) * | 2016-03-01 | 2019-01-22 | Corcept Therapeutics Inc | método para o tratamento de paciente com carga tumoral |
AU2017357329A1 (en) | 2016-11-10 | 2019-06-13 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
CN109824693B (zh) * | 2017-04-18 | 2020-12-08 | 四川大学 | Brd4抑制剂及其在肿瘤治疗药物中的应用 |
WO2019080941A1 (fr) * | 2017-10-27 | 2019-05-02 | Jacobio-Beta Pharmaceuticals Co., Ltd. | Nouveaux composés tricycliques |
MX2020014111A (es) * | 2018-06-25 | 2021-06-15 | Jacobio Pharmaceuticals Co Ltd | Compuestos triciclicos. |
CN108840868B (zh) * | 2018-08-01 | 2019-10-18 | 上海山的实业有限公司 | 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用 |
WO2020132046A1 (fr) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
WO2020200284A1 (fr) * | 2019-04-04 | 2020-10-08 | 上海华汇拓医药科技有限公司 | Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine |
CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
EP4039333A4 (fr) | 2019-09-30 | 2024-02-14 | Kyowa Kirin Co Ltd | Agent de dégradation de bet |
AU2022211285A1 (en) * | 2021-01-22 | 2023-08-17 | Jingrui Biopharma Co., Ltd. | Tricyclic compounds as anticancer agents |
EP4297750A1 (fr) * | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Utilisation d'un inhibiteur de bet seul ou en combinaison avec du fedratinib ou du ruxolitinib pour le traitement d'une malignité hématologique telle que la myélofibrose |
AU2022270984A1 (en) * | 2021-05-06 | 2023-11-23 | Raziel Therapeutics Ltd. | Crystalline carbazole derivative |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3427093A (en) * | 1992-01-15 | 1993-08-03 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
JP2007509045A (ja) | 2003-10-18 | 2007-04-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿失禁および関連疾患の処置用のgabaアゴニストとしての5−置換2−(フェニルメチル)チオ−4−フェニル−4h−1,2,4−トリアゾール誘導体および関連化合物 |
US20070269420A1 (en) * | 2003-11-24 | 2007-11-22 | Chunduru Srinivas K | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP1866339B8 (fr) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Molecules de liaison gitr et leurs utilisations |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
WO2008036642A2 (fr) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
EP1987839A1 (fr) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
EP2044949A1 (fr) | 2007-10-05 | 2009-04-08 | Immutep | Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes |
WO2009073620A2 (fr) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Inhibiteurs de l'ido |
FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
WO2010080474A1 (fr) * | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole et inhibiteurs de la carboline kinase |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
EA201201191A1 (ru) | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций |
ME03447B (fr) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées |
BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
CA2789076C (fr) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Anticorps contre les colonies humaines stimulant le recepteur du facteur-1 et ses utilisations |
TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之pbk抑制劑 |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用 |
KR101527300B1 (ko) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb 결합 분자 |
AR084312A1 (es) * | 2010-12-16 | 2013-05-08 | Genentech Inc | Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas |
US8580399B2 (en) * | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 | ||
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
WO2013046635A1 (fr) | 2011-09-28 | 2013-04-04 | 出光興産株式会社 | Substance pour élément électroluminescent organique, et élément électroluminescent organique produit en utilisant celle-ci |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
CN104159921B (zh) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP2847220A1 (fr) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Méthodes destinées à traiter des affections avec des anticorps qui se lient au récepteur du facteur 1 de stimulation des colonies (csf1r) |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
US10053454B2 (en) * | 2013-02-27 | 2018-08-21 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
EP2970312B1 (fr) * | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant |
LT3087071T (lt) * | 2013-12-24 | 2018-11-12 | Bristol-Myers Squibb Company | Tricikliniai junginiai kaip priešvėžiniai agentai |
-
2014
- 2014-12-23 LT LTEP14824743.0T patent/LT3087071T/lt unknown
- 2014-12-23 EA EA201990240A patent/EA201990240A1/ru unknown
- 2014-12-23 TN TN2016000238A patent/TN2016000238A1/en unknown
- 2014-12-23 AU AU2014369982A patent/AU2014369982B2/en active Active
- 2014-12-23 RS RS20181319A patent/RS58014B1/sr unknown
- 2014-12-23 SG SG11201605097SA patent/SG11201605097SA/en unknown
- 2014-12-23 RS RS20210158A patent/RS61479B1/sr unknown
- 2014-12-23 EP EP14824743.0A patent/EP3087071B1/fr active Active
- 2014-12-23 DK DK14824743.0T patent/DK3087071T3/da active
- 2014-12-23 CN CN201810460901.7A patent/CN108558871B/zh active Active
- 2014-12-23 HU HUE18192207A patent/HUE054183T2/hu unknown
- 2014-12-23 PL PL18192207T patent/PL3466949T3/pl unknown
- 2014-12-23 TW TW108146502A patent/TWI726544B/zh active
- 2014-12-23 US US15/107,652 patent/US20160318928A1/en not_active Abandoned
- 2014-12-23 EP EP18192207.1A patent/EP3466949B1/fr active Active
- 2014-12-23 MY MYPI2016702341A patent/MY176489A/en unknown
- 2014-12-23 LT LTEP18192207.1T patent/LT3466949T/lt unknown
- 2014-12-23 UY UY0001035916A patent/UY35916A/es unknown
- 2014-12-23 WO PCT/US2014/072031 patent/WO2015100282A1/fr active Application Filing
- 2014-12-23 PL PL14824743T patent/PL3087071T3/pl unknown
- 2014-12-23 HU HUE14824743A patent/HUE041719T2/hu unknown
- 2014-12-23 SI SI201431748T patent/SI3466949T1/sl unknown
- 2014-12-23 PE PE2016000945A patent/PE20160844A1/es unknown
- 2014-12-23 NZ NZ72232614A patent/NZ722326A/en unknown
- 2014-12-23 TW TW103145061A patent/TWI736517B/zh active
- 2014-12-23 MX MX2016007928A patent/MX369491B/es active IP Right Grant
- 2014-12-23 SI SI201430891T patent/SI3087071T1/sl unknown
- 2014-12-23 CA CA2934953A patent/CA2934953C/fr active Active
- 2014-12-23 EA EA201691070A patent/EA032469B1/ru not_active IP Right Cessation
- 2014-12-23 MA MA39211A patent/MA39211B1/fr unknown
- 2014-12-23 BR BR112016013744-2A patent/BR112016013744B1/pt active IP Right Grant
- 2014-12-23 PT PT14824743T patent/PT3087071T/pt unknown
- 2014-12-23 PT PT181922071T patent/PT3466949T/pt unknown
- 2014-12-23 ES ES18192207T patent/ES2857848T3/es active Active
- 2014-12-23 CN CN201480076189.0A patent/CN106029663B/zh active Active
- 2014-12-23 KR KR1020167019782A patent/KR102457145B1/ko active IP Right Grant
- 2014-12-23 ES ES14824743T patent/ES2698998T3/es active Active
- 2014-12-23 DK DK18192207.1T patent/DK3466949T3/da active
- 2014-12-23 JP JP2016542692A patent/JP6466456B2/ja active Active
- 2014-12-23 AR ARP140104912A patent/AR099379A1/es active IP Right Grant
-
2016
- 2016-05-24 PH PH12016500953A patent/PH12016500953A1/en unknown
- 2016-06-20 IL IL246359A patent/IL246359B/en active IP Right Grant
- 2016-06-23 CL CL2016001629A patent/CL2016001629A1/es unknown
-
2018
- 2018-11-07 HR HRP20181849TT patent/HRP20181849T1/hr unknown
- 2018-12-04 CY CY181101293T patent/CY1121076T1/el unknown
-
2019
- 2019-01-09 JP JP2019002078A patent/JP6675501B2/ja active Active
-
2021
- 2021-02-08 HR HRP20210212TT patent/HRP20210212T8/hr unknown
- 2021-03-17 CY CY20211100226T patent/CY1124061T1/el unknown
- 2021-11-03 AR ARP210103062A patent/AR123996A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
IN2015DN01156A (fr) | ||
MA35920B1 (fr) | Composés destinés au traitement de l'amyotrophie spinale | |
MA39193A1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
IN2014KN02601A (fr) | ||
MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. | |
MX2009010225A (es) | Nuevos compuestos 707 y sus usos. | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
EA201590846A1 (ru) | Клизмы | |
MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
MA38636A1 (fr) | Composés de 3,4-dihydroisoquinoléin-2(1h)-yle |